Deborah Donnell is a Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Center and the Department of Global Health at the University of Washington, Seattle. She has participated as a biostatistician in the design and analysis of seminal HIV prevention trials conducted in the United States and internationally for over 20 years, primarily with the HIV Prevention Trials Network. She was lead statistician for PrEP efficacy trials of both FTC/TDF and cabotegravir, and made integral contributions to trials testing the impact of antiretroviral treatment as prevention. Ongoing work includes both efficacy and implementation trials integrating these effective biomedical tools with behavioural and structural interventions in populations vulnerable to HIV through sexual and injection practices. Deborah is active in pursuing novel trial design approaches to advance additional HIV prevention tools.
